A Phase III, Single-Center, Randomized Controlled Trial Comparing Clinical and Cost-Effectiveness Analyses of Botulinum Toxin Uterine Injections Versus Placebo for Severe Dysmenorrhea and Chronic Pelvic Pain of Uterine Origin After Standard Therapeutic Failure. (July 2022)